Trial Information
Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Inclusion Criteria:
- Histological or cytological confirmation of locally advanced or metastatic Non Small
Cell Lung Cancer (IIIB-IV)
- Tumour sample (block of slides) available for KRAS analysis
Exclusion Criteria:
- Confirmation of locally advanced or metastatic NSCLC (IIIB-IV) exclusively by
cytology, with no tumour sample access.
- Previous treatment using a MEK inhibitor or any other regimen containing docetaxel
(previous treatment with paclitaxel is accepted)
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
To analyze the frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC.
Outcome Time Frame:
March 31, 2010
Safety Issue:
No
Principal Investigator
José Eduardo Pipolo das Neves, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca do Brasil, MC Medical Director
Authority:
Brazil: Ethics Committee
Study ID:
NIS-OBR-DUM-2008/1
NCT ID:
NCT00956280
Start Date:
September 2009
Completion Date:
April 2010
Related Keywords:
- Non Small Cell Lung Cancer
- The frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC
- KRAS mutation in population with advanced NSCLC
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms